The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
June 4, 2024
View Complete Issue         Table of Contents 2019 
Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
June 4, 2024 (Issue: 5073)
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class nitric oxide-releasing agent, has been approved by the FDA for topical treatment of molluscum contagiosum in patients ≥1 year old. It is the second drug to become available in the US...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
Article code: 5073a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.